OPTN(Delisted)
OptiNose·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 0
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OPTN
Optinose, Inc.
A pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists
1020 Stony Hill Road, Suite 300, Yardley, Pennsylvania 19067
--
OptiNose, Inc. Incorporated in Delaware in May 2010. The company is a professional pharmaceutical company focused on product development and commercialization for otolaryngology, or ENT patients, and professional treatment of allergies. The company's main product, XHANCE (flutisone) nasal spray, utilizes a unique respiratory exhalation system, or EDS, to provide one of the most effective anti-inflammatory corticosteroids for the treatment of chronic sinusitis and nasal polyps.
Company Financials
EPS
OPTN has released its 2024 Q4 earnings. EPS was reported at -0.03, versus the expected -0.84, beating expectations. The chart below visualizes how OPTN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OPTN has released its 2025 Q1 earnings report, with revenue of 18.51M, reflecting a YoY change of 24.40%, and net profit of -22.42M, showing a YoY change of -59.35%. The Sankey diagram below clearly presents OPTN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
